Trial Profile
A Phase III Randomized, Double-blind Study to Demonstrate the Antiviral Activity of Dolutegravir (DTG) 50 mg Twice Daily Versus Placebo Both Co-Administered With a Failing Antiretroviral Regimen Over Seven Days, Followed by an Open Label Phase With All Subjects Receiving DTG 50 mg Twice Daily Co-administered With an Optimised Background Regimen (OBR) in HIV-1 Infected, Integrase Inhibitor Therapy-Experienced and Resistant, Adults
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Aug 2023
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary) ; Antiretrovirals; Integrase inhibitors
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms VIKING-4
- Sponsors ViiV Healthcare
- 30 Apr 2018 Status changed from active, no longer recruiting to completed.
- 21 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 14 Sep 2012 Planned End Date changed from 1 Nov 2012 to 1 Jun 2015 as reported by ClinicalTrials.gov record.